{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:08:56Z","timestamp":1782256136532,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH","award":["T32CA148062"],"award-info":[{"award-number":["T32CA148062"]}]}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.amjsurg.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T23:27:02Z","timestamp":1560900422000},"page":"145-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rate of BRCA mutation in patients tested under NCCN genetic testing criteria"],"prefix":"10.1016","volume":"219","author":[{"given":"Anna C.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Imperiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krysten","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian M.","family":"Erdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia L.","family":"Sugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.","family":"Lizarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2019.06.012_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group","volume":"83","year":"2000","journal-title":"Br J Canc"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib3","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population frequency of germline BRCA1\/2 mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib5","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","article-title":"Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years","volume":"66","author":"Malone","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib6","series-title":"Cancer Facts & Figures","year":"2018"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib7","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-012-2348-2","article-title":"Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer","volume":"137","author":"Rummel","year":"2013","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-012-2021-9","article-title":"Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study","volume":"134","author":"Fostira","year":"2012","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib12","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng0596-123","article-title":"BRCA2 germline mutations in male breast cancer cases and breast cancer families","volume":"13","author":"Couch","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","article-title":"The prevalence of BRCA1 mutations among young women with triple-negative breast cancer","volume":"9","author":"Young","year":"2009","journal-title":"BMC Canc"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jnci\/91.14.1241","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer","volume":"91","author":"Warner","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","article-title":"Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO","volume":"94","author":"Euhus","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br J Canc"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamaoncol.2015.3856","article-title":"Delayed initiation of adjuvant chemotherapy among patients with breast cancer","volume":"2","author":"Chavez-MacGregor","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to surgery and breast cancer survival in the United States","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/1940-6207.CAPR-09-0130","article-title":"Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy","volume":"3","author":"Yi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib25","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-015-4745-3","article-title":"Negative genetic testing does not deter contralateral prophylactic mastectomy in younger patients with greater family histories of breast cancer","volume":"22","author":"Wang","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.18.01631","article-title":"Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib27","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1245\/s10434-018-6621-4","article-title":"Underdiagnosis of hereditary breast and ovarian cancer in medicare patients: genetic testing criteria miss the mark","volume":"25","author":"Yang","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-018-4727-9","article-title":"Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations","volume":"170","author":"Clifton","year":"2018","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.6004\/jnccn.2017.0107","article-title":"Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in patients with breast cancer","volume":"15","author":"Cropper","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10689-016-9921-5","article-title":"BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines","volume":"16","author":"Chun","year":"2017","journal-title":"Fam Cancer"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib33","series-title":"Concordance with BRCA1\/2 testing guidelines among women in the Health of Women (HOW) Study((R))","author":"Silver","year":"2018"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib34","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2017.76.2369","article-title":"Gaps in receipt of clinically indicated genetic counseling after diagnosis of breast cancer","volume":"36","author":"Katz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/000313481808400139","article-title":"Genetic testing for hereditary breast cancer: the decision to decline","volume":"84","author":"White","year":"2018","journal-title":"Am Surg"},{"key":"10.1016\/j.amjsurg.2019.06.012_bib36","series-title":"Consensus Guideline on Genetic Testing for Hereditary Breast Cancer","year":"2019"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961019302478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961019302478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:18:23Z","timestamp":1757701103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961019302478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0002961019302478"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2019.06.012","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rate of BRCA mutation in patients tested under NCCN genetic testing criteria","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}